Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

Effect of oral sodium bicarbonate on fibroblast growth factor-23 in patients with chronic kidney disease: a pilot study.

Chen W, Melamed ML, Hostetter TH, Bauer C, Raff AC, Almudevar AL, Lalonde A, Messing S, Abramowitz MK.

BMC Nephrol. 2016 Aug 5;17(1):114. doi: 10.1186/s12882-016-0331-6.

2.

Effects of oral sodium bicarbonate in patients with CKD.

Abramowitz MK, Melamed ML, Bauer C, Raff AC, Hostetter TH.

Clin J Am Soc Nephrol. 2013 May;8(5):714-20. doi: 10.2215/CJN.08340812. Epub 2013 Feb 7.

3.

Effect of oral sodium bicarbonate supplementation on progression of chronic kidney disease in patients with chronic metabolic acidosis: study protocol for a randomized controlled trial (SoBic-Study).

Gaggl M, Cejka D, Plischke M, Heinze G, Fraunschiel M, Schmidt A, Hörl WH, Sunder-Plassmann G.

Trials. 2013 Jul 4;14:196. doi: 10.1186/1745-6215-14-196.

4.

Does oral sodium bicarbonate therapy improve function and quality of life in older patients with chronic kidney disease and low-grade acidosis (the BiCARB trial)? Study protocol for a randomized controlled trial.

Witham MD, Band MM, Littleford RC, Avenell A, Soiza RL, McMurdo ME, Sumukadas D, Ogston SA, Lamb EJ, Hampson G, McNamee P; BiCARB Study Group.

Trials. 2015 Aug 1;16:326. doi: 10.1186/s13063-015-0843-6.

5.

Fibroblast Growth Factor 23 and Risk of CKD Progression in Children.

Portale AA, Wolf MS, Messinger S, Perwad F, Jüppner H, Warady BA, Furth SL, Salusky IB.

Clin J Am Soc Nephrol. 2016 Nov 7;11(11):1989-1998. Epub 2016 Aug 25.

6.

Randomized Clinical Trial of Sevelamer Carbonate on Serum Klotho and Fibroblast Growth Factor 23 in CKD.

Liabeuf S, Ryckelynck JP, El Esper N, Ureña P, Combe C, Dussol B, Fouque D, Vanhille P, Frimat L, Thervet E, Mentaverri R, Prié D, Choukroun G; FRENCH Study collaborators.

Clin J Am Soc Nephrol. 2017 Dec 7;12(12):1930-1940. doi: 10.2215/CJN.03030317. Epub 2017 Oct 26.

7.

Effect of Treatment of Metabolic Acidosis on Vascular Endothelial Function in Patients with CKD: A Pilot Randomized Cross-Over Study.

Kendrick J, Shah P, Andrews E, You Z, Nowak K, Pasch A, Chonchol M.

Clin J Am Soc Nephrol. 2018 Oct 8;13(10):1463-1470. doi: 10.2215/CJN.00380118. Epub 2018 Sep 20.

PMID:
30237219
9.

Effect of Omega-3 Fatty Acid Supplementation on Plasma Fibroblast Growth Factor 23 Levels in Post-Myocardial Infarction Patients with Chronic Kidney Disease: The Alpha Omega Trial.

de Borst MH, Baia LC, Hoogeveen EK, Giltay EJ, Navis G, Bakker SJL, Geleijnse JM, Kromhout D, Soedamah-Muthu SS.

Nutrients. 2017 Nov 11;9(11). pii: E1233. doi: 10.3390/nu9111233.

10.

Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5: a sequence suggested from a cross-sectional study.

Pavik I, Jaeger P, Ebner L, Wagner CA, Petzold K, Spichtig D, Poster D, Wüthrich RP, Russmann S, Serra AL.

Nephrol Dial Transplant. 2013 Feb;28(2):352-9. doi: 10.1093/ndt/gfs460. Epub 2012 Nov 4.

11.

Impact of fractional phosphate excretion on the relation of FGF23 with outcome in CKD patients.

Bech AP, Bouma-de Krijger A, van Zuilen AD, Bots ML, van den Brand JA, Blankestijn PJ, Wetzels JF, Vervloet MG.

J Nephrol. 2015 Aug;28(4):477-84. doi: 10.1007/s40620-015-0178-0. Epub 2015 Feb 21.

12.

Phosphate, fibroblast growth factor 23 and retinopathy in chronic kidney disease: the Chronic Renal Insufficiency Cohort Study.

Mehta R, Ying GS, Houston S, Isakova T, Nessel L, Ojo A, Go A, Lash J, Kusek J, Grunwald J, Wolf M; CRIC Study Investigators.

Nephrol Dial Transplant. 2015 Sep;30(9):1534-41. doi: 10.1093/ndt/gfv123. Epub 2015 Apr 24.

13.

The impact of vitamin D status on the relative increase in fibroblast growth factor 23 and parathyroid hormone in chronic kidney disease.

Taal MW, Thurston V, McIntyre NJ, Fluck RJ, McIntyre CW.

Kidney Int. 2014 Aug;86(2):407-13. doi: 10.1038/ki.2013.537. Epub 2014 Jan 15.

14.

Serum level of fibroblast growth factor 23 in maintenance renal transplant patients.

Sánchez Fructuoso AI, Maestro ML, Pérez-Flores I, Valero R, Rafael S, Veganzones S, Calvo N, De la Orden V, De la Flor JC, Valga F, Vidaurreta M, Fernández-Pérez C, Barrientos A.

Nephrol Dial Transplant. 2012 Nov;27(11):4227-35. doi: 10.1093/ndt/gfs409.

PMID:
23144073
15.

Effect of a non-calcium-based phosphate binder on fibroblast growth factor 23 in chronic kidney disease.

Spatz C, Roe K, Lehman E, Verma N.

Nephron Clin Pract. 2013;123(1-2):61-6. doi: 10.1159/000351811. Epub 2013 Jun 14.

16.

Disordered FGF23 and mineral metabolism in children with CKD.

Portale AA, Wolf M, Jüppner H, Messinger S, Kumar J, Wesseling-Perry K, Schwartz GJ, Furth SL, Warady BA, Salusky IB.

Clin J Am Soc Nephrol. 2014 Feb;9(2):344-53. doi: 10.2215/CJN.05840513. Epub 2013 Dec 5.

17.

Correction of metabolic acidosis improves insulin resistance in chronic kidney disease.

Bellasi A, Di Micco L, Santoro D, Marzocco S, De Simone E, Cozzolino M, Di Lullo L, Guastaferro P, Di Iorio B; UBI study investigators.

BMC Nephrol. 2016 Oct 22;17(1):158.

18.
20.

Acid Load and Phosphorus Homeostasis in CKD.

Khairallah P, Isakova T, Asplin J, Hamm L, Dobre M, Rahman M, Sharma K, Leonard M, Miller E 3rd, Jaar B, Brecklin C, Yang W, Wang X, Feldman H, Wolf M, Scialla JJ; Chronic Renal Insufficiency Cohort (CRIC) Study Investigators.

Am J Kidney Dis. 2017 Oct;70(4):541-550. doi: 10.1053/j.ajkd.2017.04.022. Epub 2017 Jun 21.

Supplemental Content

Support Center